Journal Article

Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial: study protocol

Amaro, Sergio, Chamorro, Angel, Vega, Pedro, Renú, Arturo, López Hernández, Nicolás, Camps‐Renom, Pol, Pérez de la Ossa, Natalia, Singla, Alba, Serena, Joaquin, Morales, Ana, Dorado, Laura, Davalos, Antonio, Fernandez-Couto, Maria Dolores, Blasco, Jordi, Herrera-Isasi, Maria, Delgado-Mederos, Raquel, Leira, Enrique C, San Roman, Luis, Valls, Joan, Laredo, Carlos, Terceño, Mikel, Castellanos, Mar, Arenillas Lara, Juan Francisco, de la Riva, Patricia, Freijo, Maria del Mar, Hernández Fernández, Francisco, Werner, Mariano, Morales-Caba, Lluis, Torres, Ferran, Oleaga, Laura, Urra, Xabier

2025

Overview

RationaleThe potential value of rescue intra-arterial thrombolysis in patients with large vessel occlusion (LVO) stroke treated with mechanical thrombectomy (MT) remains to be validated in randomised trials.AimThe Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial is designed to confirm whether adjunctive intra-arterial alteplase, administered after successful MT, improves clinical outcomes in patients with LVO stroke.Sample size estimatesA total of 440 patients (220 per group) randomised in a 1:1 ratio to receive intra-arterial thrombolysis or not intra-arterial thrombolysis provides 80% statistical power to detect a 14% absolute benefit in the primary endpoint (the proportion of patients achieving modified Rankin Scale (mRS) 0–1 at 90 days), assuming a rate of 40% in the control group, a 5% two-sided type I error. The sample size also provides >95% power for detecting an 18% absolute benefit in secondary imaging endpoints, assuming a 58% rate in the control group.Methods and designMulticentre, randomised, open, blinded end-point assessment phase III trial. Eligible patients are adults (≥18 years) with symptomatic LVO who undergo MT with successful or complete reperfusion at end of the procedure. Patients in the intervention group will receive a 15 min intra-arterial infusion of alteplase (1.0 mg/mL, maximum dose 20 mg).Study outcome(s)The primary outcome is the proportion of patients achieving excellent functional outcome (mRS 0–1) at 90 days. Key secondary outcomes are the presence of hypoperfusion on brain CT perfusion at 36±24 hours post randomisation, infarct expansion, Barthel Index and quality of life. Mortality and symptomatic intracerebral haemorrhage will also be evaluated.DiscussionThis trial will provide evidence whether rescue intra-arterial thrombolysis improves clinical outcome in patients with LVO stroke who achieve successful or complete angiographic reperfusion following MT.

• Publisher: BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Brain research / Carotid arteries / Catheters / Clinical outcomes / Clinical Trial / Hemorrhage / Informed consent / Ischemia / Ischemic Stroke / Medical imaging / Neuroimaging / Optimization / Patients / Perfusion Imaging / Protocol / Questionnaires / Randomized Controlled Trial / Stroke / Thrombolytic Therapy / Veins & arteries